Immune Checkpoint Blockade in Cancer Therapy.

By M. Postow, M. Callahan, J. Wolchok. Journal of Clinical Oncology, 2015

2,369 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/467a4967ff134d064440de989dba9bf733a265ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes (2018, background): “The limitations of IHC are particularly acute when it is necessary to quantify complex cellular states and multiple cell types, such as tumor infiltrating regulatory and cytotoxic T cells (Postow et al., 2015) in parallel with tissue and pharmaco-dynamic markers.”
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “Recently, there has been increased interest in agents targeting programmed cell death protein 1 (PD1) and its ligands (PD-L1 and PD-L2), which have made a significant impact in the treatment of traditionally difficult-to-treat diseases such as melanoma and non-small-cell lung cancer as well as other”
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “Postow et al., 2015).”
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017, background): “Immune checkpoint inhibitors, particularly agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1), are being increasingly explored as a potential treatment strategy in various cancers [7].”
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (2016, background): “Other MRX34-related AEs that tended to occur later postinfusion, such as diarrhea/enteritis, fatigue, alteredmental status, and dyspnea/hypoxia, could potentially be immune-related toxicities similar to those that occur with the anti-CTLA-4 and antiPD-1/PD-L1 immune checkpoint inhibitors [41].”
Non-coding RNAs in disease: from mechanisms to therapeutics (2023, neutral): “299,300).”
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies (2015, background): “Ipilimumab (Yervoy; Bristol-Myers Squibb) is a humanized IgG1monoclonal antibody thatblocksCTLA-4 signalingand is FDA approved for advancedmelanoma (6).”
Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors (2016, neutral): “While these antibodies are often effective, many patients do not show a response or have significant adverse effects from treatment (Postow et al., 2015).”
Deubiquitination and Stabilization of PD-L1 by CSN5 (2016, background): “Similar to the enhanced efficacy observed for the anti-PD-1 and anti-CTLA4 combination therapy (Postow et al., 2015), the combination of curcumin and anti-CTLA4 therapy in 4T1 breast cancer, B16 melanoma, and CT26 colon cancer syngeneic mouse models did not induce any substantial changes in body…”
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer (2017, neutral): “The role of the immune system in tumour progression has been extensively studied, and the results of these studies have provided the basis for successful immunotherapy in multiple cancer types 12,42 .”